60,432 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Bought by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC purchased a new position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the 4th quarter, Holdings Channel.com reports. The firm purchased 60,432 shares of the company’s stock, valued at approximately $805,000.

Several other large investors also recently bought and sold shares of ETON. Wasatch Advisors LP bought a new stake in Eton Pharmaceuticals in the third quarter worth $1,431,000. Westside Investment Management Inc. increased its position in Eton Pharmaceuticals by 5.7% in the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock worth $3,711,000 after purchasing an additional 33,275 shares during the last quarter. Geode Capital Management LLC increased its position in Eton Pharmaceuticals by 13.5% in the third quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after purchasing an additional 32,365 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft bought a new stake in Eton Pharmaceuticals in the fourth quarter worth $373,000. Institutional investors own 27.86% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Craig Hallum lifted their price objective on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. HC Wainwright lifted their price objective on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Finally, B. Riley assumed coverage on shares of Eton Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $21.00 price objective for the company.

Eton Pharmaceuticals Stock Up 1.6 %

NASDAQ ETON opened at $15.70 on Friday. The company has a fifty day moving average of $14.96 and a two-hundred day moving average of $10.37. The firm has a market capitalization of $409.00 million, a price-to-earnings ratio of -71.36 and a beta of 1.40. Eton Pharmaceuticals, Inc. has a 52 week low of $3.03 and a 52 week high of $18.41.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.